JAKAVI reduced spleen volume in the majority of patients

Demonstrated improvement in patients with enlarged spleen size^1-3

• 38% of patients in the JAKAVI arm met the spleen response criterion (≥35% reduction in volume at Week 32) vs 1% in the BAT arm^1,2
• Spleen response (spleen volume reduction ≥35%) was one of the components of the composite primary endpoint^1,2

• Spleen size reduced in nearly three-quarters of all patients receiving JAKAVI³
  • Proportion of patients with any spleen size reduction was an exploratory analysis
• Spleen volume ≥450 cm³ was included in the eligibility criteria for the trial¹

Next: Well-characterised safety profile of JAKAVI